Entity Details
| Primary name |
GALNS_HUMAN |
| Entity type |
UniProt |
| Source |
Source Link |
Details
| Accession | P34059 |
| EntryName | GALNS_HUMAN |
| FullName | N-acetylgalactosamine-6-sulfatase |
| TaxID | 9606 |
| Evidence | evidence at protein level |
| Length | 522 |
| SequenceStatus | complete |
| DateCreated | 1994-02-01 |
| DateModified | 2021-06-02 |
Subcellular Location
Show/Hide Table
| Subcellular Location |
| Lysosome |
Domains
Show/Hide Table
| Domain | Name | Category | Type |
| IPR000917 | Sulfatase, N-terminal | Domain | Domain |
| IPR017850 | Alkaline-phosphatase-like, core domain superfamily | Family | Homologous superfamily |
| IPR024607 | Sulfatase, conserved site | Site | Conserved site |
| IPR035626 | N-acetylgalactosamine-6-sulfatase | Family | Family |
Diseases
Show/Hide Table
| Disease ID | Source | Name | Description |
| 253000 | OMIM | Mucopolysaccharidosis 4A (MPS4A) | A form of mucopolysaccharidosis type 4, an autosomal recessive lysosomal storage disease characterized by intracellular accumulation of keratan sulfate and chondroitin-6-sulfate. Key clinical features include short stature, skeletal dysplasia, dental anomalies, and corneal clouding. Intelligence is normal and there is no direct central nervous system involvement, although the skeletal changes may result in neurologic complications. There is variable severity, but patients with the severe phenotype usually do not survive past the second or third decade of life. The disease is caused by variants affecting the gene represented in this entry. |
Drugs
Show/Hide Table
| Drug | Name | Source | Type |
| DB09301 | Chondroitin sulfate | Drugbank | small molecule |
Interactions
2 interactions